Claims
- 1. A pullulan derivative having one or more active sites resulting from introduction of sulfuric acid, phosphoric acid, a sulfonic acid or a carboxylic acid, wherein one hydrogen atom of the group of the formula ##STR33## occurring at said active sites is partly substituted by a group of the formula ##STR34## wherein L.sup.1 and L.sup.2 each independently is amine or a unidentate ligand amine or combinedly represent a bidentate ligand amine and Y is an anionic ligand, and/or two hydrogen atoms of the group ##STR35## groups bound to one and the same carbon atom or to two neighboring carbon atoms as occurring at said active sites are, each independently, partly substituted by a group of the formula ##STR36## wherein L.sup.1 and L.sup.2 are as defined above, or a pharmacologically acceptable salt thereof.
- 2. A process for producing a pullulan derivative having one or more active sites resulting from introduction of sulfuric acid, phosphoric acid, a sulfonic acid or a carboxylic acid, wherein one hydrogen atom of the group of the formula ##STR37## occurring at said active sites is partly substituted by a group of the formula ##STR38## wherein L.sup.1 and L.sup.2 each independently is amine or a unidentate ligand amine or combinedly represent a bidentate ligand amine and Y is an anionic ligand, and/or two hydrogen atoms of the group ##STR39## groups bound to one and the same carbon atom or to two neighboring carbon atoms as occurring at said active sites are, each independently, partly substituted by a group of the formula ##STR40## wherein L.sup.1 and L.sup.2 are as defined above, and/or a pharmacologically acceptable salt thereof which comprises reacting pullulan with a reagent capable of introducing sulfuric acid, phosphoric acid, a sulfonic acid or a carboxylic acid into pullulan, then reacting the thus-obtained activated pullulan with a cis-platinum(II) complex of the formula ##STR41## wherein L.sup.1 and L.sup.2 are as defined above and X.sup.1 and X.sup.2 each is nitrato or hydroxo or combinedly represent sulfato, to obtain a pullulan derivative having one or more active sites resulting from introduction of sulfuric acid, phosphoric acid, a sulfonic acid or a carboxylic acid, wherein one hydrogen atom of the group of the formula ##STR42## occurring at said active sites is partly substituted by a group of the formula ##STR43## wherein L.sup.1 and L.sup.2 are as defined above and X.sup.3 is nitrato or hydroxo or sulfato (said sulfato being the remainder sulfato resulting from binding of one of X.sup.1 and X.sup.2 to the activated pullulan), and/or two hydrogen atoms of the group ##STR44## groups bound to one and the same carbon atom or to two neighboring carbon atoms as occurring at said active sites are, each independently, partly substituted by a group of the formula ##STR45## wherein L.sup.1 and L.sup.2 are as defined above, and/or a salt thereof, and, as required, reacting the thus-obtained pullulan derivative and/or a salt thereof with an anion-forming compound, selected from the group consisting of alkali metal salts, alkaline earth metal salts and ammonium salts of organic and inorganic acids to obtain a pullulan derivative having one or more active sites resulting from introduction of sulfuric acid, phosphoric acid, a sulfonic acid or a carboxylic acid, wherein one hydrogen atom of the group of the formula ##STR46## occurring at said active sites is partly substituted by a group of the formula ##STR47## wherein L.sup.1 and L.sup.2 are as defined above and X.sup.4 is an anionic ligand, and/or two hydrogen atoms of the group ##STR48## groups bound to one and the same carbon atom or to two neighboring carbon atoms as occurring at said active sites are, each independently, partly substituted by a group of the formula ##STR49## wherein L.sup.1 and L.sup.2 are as defined above, and/or a salt thereof.
- 3. A pharmaceutical composition which comprises a therapeutically effective amount of at least one pullulan derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 and a pharmaceutically acceptable carrier therefor.
- 4. An anticancer agent which comprises as an active ingredient a pullulan derivative or a pharmacologically acceptable salt thereof as claimed in claim 1.
- 5. A method of treating cancer in a host which comprising administering thereto a therapeutically effective amount of at least one pullulan derivative or a pharmacologically acceptable salt thereof as claimed in claim 1 effective for said treatment.
- 6. A pullulan derivative having one or more active sites resulting from introduction of sulfuric acid, phosphoric acid, a sulfonic acid or a carboxylic acid, wherein one hydrogen atom of the group of the formula ##STR50## occurring at said active sites is partly substituted by a group of the formula ##STR51## is d-trans-1,2-diaminocyclohexane and Y is an anionic ligand, and/or two hydrogen atoms of the group ##STR52## groups bound to one and the same carbon atom or to two neighboring carbon atoms as occurring at said active sites are, each independently, partly substituted by a group of the formula ##STR53## is as defined above, or a pharmacologically acceptable thereof.
Priority Claims (3)
Number |
Date |
Country |
Kind |
61-117969 |
May 1986 |
JPX |
|
62-52273 |
Mar 1987 |
JPX |
|
63-243616 |
Sep 1988 |
JPX |
|
Parent Case Info
This application is a continuation-in-part of U.S. patent application Ser. No. 07/163,961, filed as PCT/JP87/00322, May 20, 1987, now U.S. Pat. No. 4,948,784.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4767874 |
Shima et al. |
Aug 1988 |
|
4948784 |
Mori et al. |
Aug 1990 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0099133 |
Jan 1984 |
EPX |
0190464 |
Aug 1986 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Chemical Abstracts, vol. 90, 1979, p. 46, abstract No. 48459s, Columbus Ohio, U.S.; E. Heinen et al. |
Chemical Abstracts, vol. 77, No. 13, 25th Sep. 1972, p. 1, abstract No. 83330w, Columbus, Ohio, U.S.; A. J. Thomson et al. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
163961 |
Jan 1988 |
|